Oculis Holding AG (OCS)

USD 17.35

(-0.8%)

Market Cap (In USD)

706.93 Million

Revenue (In USD)

883 Thousand

Net Income (In USD)

-88.8 Million

Avg. Volume

21.29 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.105-18.0
PE
-
EPS
-
Beta Value
0.008
ISIN
CH1242303498
CUSIP
-
CIK
1953530
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Riad Sherif M.B.A., M.D.
Employee Count
-
Website
https://oculis.com
Ipo Date
2021-05-18
Details
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.